Calithera Biosciences, Inc. (CALA) Reaches $7.74 After 8.00% Up Move; Shorts at CHEMTRADE LOGISTICS (CGIFF) Lowered By 7.03%

February 16, 2018 - By Winifred Garcia

CHEMTRADE LOGISTICS (OTCMKTS:CGIFF) had a decrease of 7.03% in short interest. CGIFF’s SI was 11,900 shares in February as released by FINRA. Its down 7.03% from 12,800 shares previously. With 4,200 avg volume, 3 days are for CHEMTRADE LOGISTICS (OTCMKTS:CGIFF)’s short sellers to cover CGIFF’s short positions. The stock increased 3.53% or $0.4597 during the last trading session, reaching $13.4998. About 2,594 shares traded or 117.98% up from the average. Chemtrade Logistics Income Fund (OTCMKTS:CGIFF) has 0.00% since February 16, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock of Calithera Biosciences, Inc. (NASDAQ:CALA) is a huge mover today! The stock increased 11.33% or $0.79 during the last trading session, reaching $7.74. About 1.05 million shares traded or 76.96% up from the average. Calithera Biosciences, Inc. (NASDAQ:CALA) has risen 278.82% since February 16, 2017 and is uptrending. It has outperformed by 262.12% the S&P500.The move comes after 5 months positive chart setup for the $274.50M company. It was reported on Feb, 16 by Barchart.com. We have $8.36 PT which if reached, will make NASDAQ:CALA worth $21.96M more.

Investors sentiment decreased to 1.22 in 2017 Q3. Its down 2.03, from 3.25 in 2017Q2. It is negative, as 16 investors sold Calithera Biosciences, Inc. shares while 21 reduced holdings. 14 funds opened positions while 31 raised stakes. 25.24 million shares or 49.47% less from 49.95 million shares in 2017Q2 were reported. State Of Wisconsin Investment Board has 0% invested in Calithera Biosciences, Inc. (NASDAQ:CALA). Bancorporation Of Ny Mellon Corp holds 109,990 shares or 0% of its portfolio. The Pennsylvania-based Nationwide Fund has invested 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Citadel Advsr Limited Co owns 0.01% invested in Calithera Biosciences, Inc. (NASDAQ:CALA) for 480,673 shares. Viking Glob Investors L P holds 0.27% in Calithera Biosciences, Inc. (NASDAQ:CALA) or 2.62 million shares. Panagora Asset Mgmt has invested 0.01% in Calithera Biosciences, Inc. (NASDAQ:CALA). Aqr Capital Mgmt Ltd Company owns 0.01% invested in Calithera Biosciences, Inc. (NASDAQ:CALA) for 496,274 shares. Credit Suisse Ag stated it has 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Bnp Paribas Arbitrage invested in 0% or 3,304 shares. Wells Fargo And Mn reported 33,742 shares stake. Rhumbline Advisers holds 34,585 shares or 0% of its portfolio. Invesco Ltd reported 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Wellington Mgmt Grp Inc Ltd Liability Partnership has invested 0.02% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA). Clarivest Asset Ltd Liability Corp reported 49,474 shares. Tower Research Cap Ltd Company (Trc) holds 174 shares or 0% of its portfolio.

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $274.50 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize SymbioscienceÂ’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

Analysts await Calithera Biosciences, Inc. (NASDAQ:CALA) to report earnings on March, 15. They expect $-0.24 earnings per share, up 46.67% or $0.21 from last year’s $-0.45 per share. After $-0.17 actual earnings per share reported by Calithera Biosciences, Inc. for the previous quarter, Wall Street now forecasts 41.18% negative EPS growth.

Among 5 analysts covering Calithera Biosciences (NASDAQ:CALA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Calithera Biosciences had 10 analyst reports since July 24, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, January 5 by H.C. Wainwright. The firm has “Buy” rating given on Friday, February 16 by Citigroup. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9. The stock has “Neutral” rating by Citigroup on Tuesday, January 24. H.C. Wainwright maintained Calithera Biosciences, Inc. (NASDAQ:CALA) on Tuesday, March 28 with “Buy” rating. H.C. Wainwright maintained it with “Buy” rating and $1900 target in Monday, June 12 report. The firm earned “Buy” rating on Friday, July 24 by Citigroup. Citigroup initiated the shares of CALA in report on Tuesday, October 25 with “Sell” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Winifred Garcia

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: